Skip to main content
TISSUE REGENIX GROUP PLC logo

TISSUE REGENIX GROUP PLC — Investor Relations & Filings

Ticker · TRX ISIN · GB00BNTXR104 LEI · 213800PNOD5UHQUFJI36 IL Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-08-21 Report Publication Anno…
Country GB United Kingdom
Listing IL TRX

About TISSUE REGENIX GROUP PLC

https://www.tissueregenix.com/

Tissue Regenix Group PLC is a medical technology company specializing in regenerative medicine. The company develops and commercializes biological products designed to repair and regenerate human tissue. It employs proprietary decellularization platform technologies to process human and animal tissues, creating acellular scaffolds. When implanted, these scaffolds support the patient's own cells in repopulating and regenerating the damaged area. The company's portfolio serves three main clinical areas: biosurgery for complex wound care, orthopaedics for sports medicine and bone graft substitutes, and dental applications for tissue and bone repair. Key products include DermaPure®, OrthoPure® XT, and the Matrix® line of bone graft substitutes.

Recent filings

Filing Released Lang Actions
Notice of interim results
Report Publication Announcement Classification · 1% confidence The document is very short (3674 characters) and its primary purpose is to announce that the company will release its interim results on a future date (September 5, 2023) and that management will host an online presentation regarding those results. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than the report itself (which would likely be an IR or ER). The text explicitly states 'Notice of interim results' and details the investor briefing, confirming it is an announcement about future reporting events.
2023-08-21 English
Half-Year Trading Update
Earnings Release Classification · 1% confidence The document is a short announcement (4834 characters) released via RNS (Regulatory News Service) from Tissue Regenix Group PLC. It provides an 'unaudited trading update for the six months ended 30 June 2023' and includes key financial highlights (revenue, EBITDA expectation) for the half-year period. Crucially, it concludes with a 'Notice of Results' stating the Group 'will publish its interim results on Tuesday, 5 September 2023.' Because this document is a brief update announcing future results publication rather than the full interim report itself, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim Report (IR) nor the Annual Report (10-K). H1 2023
2023-07-17 English
Distribution agreement for OrthoPure® XT in the UK
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 4187F' and is dated '10 July 2023'. It announces a 'Multi-year distribution agreement for OrthoPure® XT signed in the UK' between Tissue Regenix Group plc and Joint Operations Ltd. The text is a formal announcement of a business development/contract signing, not a full financial report (like 10-K or IR), a proxy statement (DEF 14A), or an earnings release (ER). Since it is a general, timely announcement distributed via the RNS system, and it doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate general regulatory announcement category is RNS (Regulatory Filings). The document length (7946 chars) is substantial enough that it is the announcement itself, not just a brief notice pointing to an attachment, although it is distributed via RNS.
2023-07-10 English
Distribution agreement with Australian Allografts
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5815A' and concludes with boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a new multi-year distribution agreement for a medical product. This structure strongly indicates a regulatory news service announcement. Since it is a general, timely corporate announcement that doesn't fit specific categories like ER, DIV, or DIRS, the most appropriate classification is the general regulatory filing category.
2023-05-25 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 8177Y' and contains the standard boilerplate text indicating it is provided by RNS, the news service of the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in voting rights thresholds crossed by a shareholder (Richard Sneller). This type of filing, reporting insider or major shareholder transactions/holdings changes, falls under the category of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the form explicitly details the crossing of a major holding threshold (from 12.0% to 13.0%) and is a regulatory notification disseminated via RNS, 'Major Shareholding Notification' (MRQ) is the most precise fit among the provided options, although 'DIRS' could also apply if the person was strictly a director. Given the structure and purpose of TR-1 forms, MRQ is appropriate. However, since TR-1 forms are often broadly categorized as regulatory disclosures about ownership changes, and 'MRQ' is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)', this is the best match. If MRQ was not available, DIRS or RNS would be considered. Given the specific nature of the content, MRQ is selected.
2023-05-09 English
Result of AGM, Share Reorganisation &TVR
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states it is announcing the 'Result of AGM, Share Reorganisation & Total Voting Rights' for Tissue Regenix Group plc. It details the results of proxy votes for all resolutions presented at the Annual General Meeting (AGM) held earlier that day. This content directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including voting outcomes. Although it contains voting results (which could overlap with DVA), the primary context is the outcome of the AGM itself, making AGM-R the most precise fit. The RNS Number and the closing statement confirm it is a regulatory announcement, but the specific content dictates the classification.
2023-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.